

“DMD #18184”

**Hepatic UDP-Glucuronosyltransferases Responsible for Glucuronidation of  
Thyroxine T<sub>4</sub> in Humans**

**Yoshihisa Kato, Shin-ichi Ikushiro, Yoshikazu Emi, Sekihiro Tamaki, Hiroshi Suzuki,  
Toshiyuki Sakaki, Shizuo Yamada, and Masakuni Degawa**

*Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Sanuki, Kagawa  
769-2193, Japan(Y.K.)*

*Faculty of Engineering, Toyama Prefectural University, Toyama 939-0398, Japan (S.I.,  
T.S.)*

*Graduate School of Life Science, University of Hyogo, Harima Science Park City,  
Hyogo 678-1297, Japan(Y.E.)*

*§School of Pharmaceutical Sciences and Global Center of Excellence Program,  
University of Shizuoka, Shizuoka 422-8526, Japan(S.T., H.S., S.Y., M.D.)*

“DMD #18184”

Running title: Human UGTs responsible for T<sub>4</sub>-glucuronidation

Address correspondence to: Dr. Yoshihisa Kato, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, 1314-1 Shido, Sanuki-city, Kagawa 769-2193, Japan. E-mail: kato@kph.bunri-u.ac.jp

Number of text pages: 15

Number of table: 1

Number of figures: 7

Number of references: 4

Number of footnotes: 1

Number of legends for figures: 3

Number of words in the Abstract: 223

Number of words in the Introduction: 237

Number of words in the Discussion: 619

ABBREVIATIONS: ST232,  
26,26,26,27,27,27-hexafluoro-1 $\alpha$ ,23(S),25-trihydroxyvitamin D<sub>3</sub>; T<sub>4</sub>, thyroxine; UGT,  
UDP-glucuronosyltransferase.

### Abstract

To clarify the UDP-glucuronosyltransferase (UGT) isoform(s) responsible for the glucuronidation of thyroid hormone thyroxine  $T_4$  ( $T_4$ ) in the human liver, the  $T_4$ -glucuronidation activities of recombinant human UGT isoforms and 7 individual human liver microsomes were comparatively examined. Among the 12 recombinant human UGT1A and UGT2B subfamily enzymes examined, UGT1A1, UGT1A3, UGT1A9 and UGT1A10 showed definite activities for  $T_4$ -glucuronidation. These UGT1A enzymes, with an exception of UGT1A10, were detected in all the human liver microsomes examined. Interindividual difference in  $T_4$ -glucuronidation activity was observed among the 7 individual human liver microsomes, and the  $T_4$ -glucuronidation activity was closely correlated with  $\beta$ -estradiol 3-glucuronidation activity. Furthermore, Spearman correlation analysis for a relationship between the  $T_4$ -glucuronidation activity and the level of UGT1A1, UGT1A3, or UGT1A9 in the microsomes revealed that levels of UGT1A1 and UGT1A3, but not UGT1A9, were closely correlated with  $T_4$ -glucuronidation activity.  $T_4$ -glucuronidation activity in human liver microsomes was strongly inhibited by 26,26,26,27,27,27-hexafluoro-1 $\alpha$ ,23(S),25-trihydroxyvitamin  $D_3$  (an inhibitor of UGT1A3), moderately by either bilirubin (an inhibitor of UGT1A1) or  $\beta$ -estradiol (an inhibitor of UGT1A1 and UGT1A9), but not by propofol (an inhibitor of UGT1A9). These findings strongly indicated that glucuronidation of  $T_4$  in the human liver was mediated by UGT1A subfamily enzymes, especially UGT1A1 and UGT1A3, and further suggested that the interindividual difference would come from that in the expression levels of UGT1A1 and UGT1A3 in individual human livers.

## Introduction

Thyroid hormone, a thyroxine  $T_4$  ( $T_4$ ), is metabolized via deiodination, *O*-glucuronidation, *O*-sulfation, ether bond cleavage and/or oxidative deamination (Visser, 1996; Wu et al., 2005). Among these metabolisms, *O*-glucuronidation is considerably important, because it is responsible for the metabolism of many endogenous and exogenous chemicals (Iyanagi, T., 2007; Radomska-Pandya et al., 1999). Visser (1996) had firstly reported that  $T_4$ -glucuronidation was mediated by UDP-glucuronosyltransferase 1A (UGT1A) subfamily enzymes, especially UGT1A1 and UGT1A6, in the rat liver. On the other hand, it had been reported that  $T_4$ -glucuronidation in the human liver was mediated mainly by UGT1A1 and UGT1A9 (Visser et al., 1993; Findlay et al., 2000). Quite recently, Yamanaka et al. (2007) have reported that the  $T_4$ -glucuronidation activity in human liver is mainly catalyzed by UGT1A1.

However, these previous studies on contribution of the UGT subfamily enzymes responsible for  $T_4$ -glucuronidation in rats and humans have been performed using only limited samples and/or techniques. The UGT isoform(s) for the  $T_4$ -metabolism is not clearly determined. In addition, the UGT genes are divided into two families, *UGT1* and *UGT2*, based on a homology of the amino acid sequence (Mackenzie et al., 2005). In the present study, to further clarify the human UGT isoform(s) responsible for  $T_4$ -glucuronidation, we examined comparatively the activities of the 12 recombinant human UGTs, including UGT1 and UGT2 family enzymes, and further determined a relationship between  $T_4$ -glucuronidation activity and levels of UGT subfamily enzymes in 7 individual human liver microsomes.

## Materials and Methods

**Materials.** UDP-glucuronic acid, alamethicin, and propofol were purchased from Sigma-Aldrich (St. Louis, MO). 26,26,26,27,27,27-hexafluoro-1 $\alpha$ ,23(S),25-trihydroxyvitamin D<sub>3</sub> (ST232), a probe substrate for UGT1A3 (Kasai et al., 2005), was kindly donated from Sumitomo pharmaceuticals (Osaka, Japan) and used a selective inhibitor of UGT1A3. Its chemical structure is shown in Fig. 1. The [<sup>125</sup>I]T<sub>4</sub> (116 Ci/mmol) radiolabeled <sup>125</sup>I at 5' position of the outer ring was obtained from PerkinElmer Life Sci., Inc. (Boston, MA).

Human liver microsomes from 7 individual human livers (HH2, HH13, HH47, HG3, HG32, HG64, and HG74) with the data on UGT activities toward  $\beta$ -estradiol, trifluoperazine, and propofol were purchased from BD Gentest (Woburn, MA). The recombinant human UGT isoforms, such as UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15, and UGT2B17, which are expressed in the insect cells (Supersomes) infected with the corresponding UGT gene-inserted baculovirus, were purchased from BD Genetest. Likewise, the microsomes from the insect cells infected with wild-type baculovirus (without a UGT gene) were purchased and used as a control (without UGTs).

**Preparation of anti-human UGT antibody.** The peptide KWLPQNDLLGHPKA deduced from a UGT2B15 cDNA sequence (356–369) (Green et al., 1994) was used as a UGT-antigen and immunized to rabbits as described previously (Ikushiro et al., 1995). The established antibody, which is cross-reactive with all the UGT1A and UGT2B

subfamily isoforms examined, was designated as an anti-human UGT.

**Immunoblot analysis.** Amount of each UGT isoform expressed in insect cells was determined by the Western blotting with an anti-human UGT. To obtain clear band on the immunoblot, a portion (20  $\mu$ l) of microsomal fraction containing human UGT(s) was treated with endoglycosidase H (200 units) for 60 min at 37°C, and the reaction was terminated by heating at 98°C for 5 min. The endoglycosidase H-treated microsomal fraction was subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE was performed using a 4% stacking and 10% separating gel. After SDS-PAGE, the separated proteins on a gel were transferred to a nitrocellulose sheet by a semi-dry blotting method. The proteins bound to an anti-human UGT on a sheet were detected using chemical luminescence (ECL detection kit; Amersham Biosciences Inc., Piscataway, NJ). Amounts of UGT1A and UGT2B proteins in the microsomes were estimated using maltose binding protein (MBP)-UGT1AC and MBP-UGT2B7C fusion proteins (New England Biolabs), respectively, as standards. In addition, amounts of the fusion proteins were determined by a bicinchoninic acid protein assay.

Levels of UGT isoforms in human liver microsomes were measured by the Western blotting with either anti-h1AC (anti-human UGT1A antibody) or isoform-specific antibodies (anti-h1A1, anti-h1A3, anti-h1A9, and anti-2B7), as described previously (Ikushiro et al., 2006). In addition, a portion (20  $\mu$ g or 40  $\mu$ g protein/lane) of microsomal preparation was treated with endoglycosidase H and then used for the Western blot analysis. Levels of UGT isoforms in individual human microsomes were shown as a ratio to that of the respective isoforms expressed in a human sample HG3.

“DMD #18184”

**Glucuronidation Assay.** Microsomal T<sub>4</sub>-glucuronidation activity was determined according to the method of Barter and Klaassen (1992). Briefly, the microsomal preparation (2.0 mg protein) with each human recombinant UGT or human liver microsomal preparation (2.0 mg protein) was added to the reaction medium (final volume 1ml) containing 0.1 mg alamethicin, 13.2 mM MgCl<sub>2</sub>, 66 mM Tris-HCl (pH 7.4), 1.26 mM saccharic acid-1,4-lactone and 4 mM UDP-glucuronic acid. The reaction was initiated by the addition of 90 μM T<sub>4</sub> solution containing [<sup>125</sup>I]T<sub>4</sub> (40-65 μCi/μmol), performed at 37°C for 4 h, and terminated by the addition of ice-cold ethanol (500 μl). After centrifugation of the reaction mixture, the resultant supernatant was used for the assay. An aliquot (50 μl) of a supernatant fraction was applied to an LK6DF silica gel-coated TLC plate (Whatman) and then developed with the solution containing ethyl acetate, methyl ethyl ketone, formic acid, and water (50 : 30 : 10 : 10). After separation by the TLC, the entire plate was scraped in 5 mm fractions, and radioactivity on each fraction was measured by γ-scintillation spectrometry (PerkinElmer, Inc., Waltham, MA).

**Effects of several UGT inhibitors on microsomal T<sub>4</sub>-glucuronidation.** Bilirubin, ST232, and propofol were used as typical inhibitors of UGT1A1 (Senafi et al., 1994; King et al., 1996), UGT1A3 (Kasai et al., 2005), and UGT1A1/UGT1A9 (Burchell et al., 1995), respectively. A human liver microsomal preparation (HH13), which contained a lot of UGT1A1, UGT1A3, and UGT1A9, was selected as an enzyme source, and inhibitory effects of bilirubin, ST232, and propofol on the microsomal activity for T<sub>4</sub>-glucuronidation were examined by the method described in the "Glucuronidation

“DMD #18184”

assay”.

**Correlation analysis.** Correlation analyses between the glucuronidation activity toward T<sub>4</sub> or other substrates and the level of UGT1A isoforms in 7 individual human liver microsomes were performed by linear regression.



## Results

**Expression levels of the UGT 1A and 2B isoforms in the insect cells transfected human UGT genes.** The quantitative immunoblot analyses with the anti-UGT cross-reactive with microsomal UGT1A and UGT2B isoforms were performed using the corresponding MBP-UGT fusion proteins as standards. As judged by Western blot analysis, amounts of microsomal UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15 and UGT2B17 in the insect cells expressing the corresponding human recombinant UGT isoforms were 1.6, 0.9, 1.2, 1.4, 1.3, 1.1, 1.1, 1.2, 0.8, 0.6, 0.6 or 0.8 nmol/mg protein, respectively.

**T<sub>4</sub>-glucuronidation by recombinant human UGT isoforms.** T<sub>4</sub>-glucuronidation activities of 12 human UGTs, including 8 UGT1A subfamily and 4 UGT2B subfamily isoforms, were examined. All the UGT isoforms examined showed definite activities for T<sub>4</sub>-glucuronidation (Fig. 2). As judged by glucuronidation activity [ $v/E_0$  ( $\text{min}^{-1}$ )], UGT1A1, UGT1A3, UGT1A8, UGT1A9, UGT1A10 and UGT2B7 showed higher capacities than the other UGT isoforms examined. In addition, UGT1A8, an extrahepatic enzyme (Cheng et al., 1998; Gregory et al., 2004), showed the highest activity.

**Inter-individual variation of T<sub>4</sub>-glucuronidation activity in the human livers.** In general, microsomal glucuronidation activity is increased by perturbation of microsomal membranes (Guéraud and Paris, 1998). Therefore, effect of alamethicine, a pore-forming oligopeptide, on the T<sub>4</sub>-glucuronidation activity of human liver

“DMD #18184”

microsomes (HH13) was firstly examined. As shown in Table 1, addition of alamethicin (0.04-0.20 mg/ml reaction mixture) resulted in increase in the glucuronidation activity of the human microsomes. Therefore, in the present experiment, the T<sub>4</sub>-glucuronidation activity was measured in the assay system with alamethicin (0.1 mg/ml reaction mixture).

Microsomal fractions were independently prepared from 7 individual human livers, HH2, HH13, HH47, HG3, HG32, HG64 and HG74, and their T<sub>4</sub>-glucuronidation activities were comparatively examined. Although all the human microsomes examined showed definite activities for T<sub>4</sub>-glucuronidation, there is an inter-individual difference (Fig. 3). The microsomes from HH13, HH64, and HH74 had the highest activities among the samples examined.

**UGT activities toward T<sub>4</sub>, β-estradiol, trifluoperazine and propofol of the human liver microsomes.** A correlation between T<sub>4</sub>-UGT activity and the UGT activities toward other typical UGT substrates, such as β-estradiol, trifluoperazine and propofol, of human liver microsomes was examined. To this purpose, the data on the UGT activities toward β-estradiol, trifluoperazine, and propofol of each human given from BD Genetest were used. As shown in Fig. 4, T<sub>4</sub>-UGT activity was closely correlated with the activity of β-estradiol 3-glucuronidation ( $r=0.729$ ,  $P<0.05$ ), while it showed no correlation with the UGT activities for trifluoperazine and propofol.

**Western blot analysis of UGT1A subfamily enzymes in human liver microsomes.** Western blot analyses with anti-h1AC and several anti-UGT1A isoform-specific antibodies were performed to determine the UGT isoforms expressed in human liver

“DMD #18184”

microsomes. The anti-h1AC could cross-react with the human UGT1A isoforms, while anti-h1A1, anti-h1A3, anti-h1A9, and anti-2B7 antibodies are specifically reactive with UGT1A1, UGT1A3, UGT1A9, and UGT2B7 respectively (Ikushiro et al., 2006).

Amount of total UGT1A isoforms (UGT1As) detected with an anti-h1AC was the greatest in the human liver sample HH47 among the 7 individual human samples (Fig. 5). On the other hand, amount of UGT1A1 determined with anti-UGT1A1 was in the order as follows: HH13>(HG74, HH2, HH47, HG64)>HH32, HG3. Concerning the UGT1A3, the order was HG64>(HG74>HH13, HG32, HH47)>HH2, HG3. In addition, amounts of UGT1A9 and UGT2B7 were not significantly different among the human samples examined.

#### **UGT isoforms responsible for T<sub>4</sub>-glucuronidation in human liver microsomes.**

The relative expression levels of UGT1A, UGT1A1, UGT1A3, and UGT1A9 in individual human liver microsomes were determined, and a relationship between the level of each UGT isoform and the T<sub>4</sub>-UGT activity was examined. The T<sub>4</sub>-UGT activity was closely correlated with the level of either UGT1A1 ( $r= 0.738$ ,  $P<0.05$ ) or UGT1A3 ( $r= 0.804$ ,  $P<0.01$ ) (Fig. 6). On the other hand, no correlation between the T<sub>4</sub>-UGT activity and the level of UGT1A9 or total UGT1As was observed.

#### **Inhibition of T<sub>4</sub>-UGT activity by UGT inhibitors in human liver microsomes.**

Effects on microsomal T<sub>4</sub>-UGT activity of the UGT inhibitors with different specificities were examined using a human liver sample HH13, which had definite levels of UGT1A1, UGT1A3, and UGT1A9. The inhibitors, with an exception of propofol, significantly decreased the T<sub>4</sub>-UGT activity (Fig. 7). Especially, addition of

“DMD #18184”

ST232 (0.4 mM) to the reaction mixture resulted in 75%-decrease in T<sub>4</sub>-UGT activity. In contrast, propofol (0.4 mM) showed little inhibitory effect on the microsomal T<sub>4</sub>-UGT activity.

## Discussion

In the present experiments, T<sub>4</sub>-UGT activities of human UGT isoforms, such as UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15 and UGT2B17, were comparatively examined. The results revealed that all the UGTs examined showed definite T<sub>4</sub>-glucuronidation activities. Among the UGTs examined, UGT1A8 showed the strongest activity. However, UGT1A8 was not detected in human liver microsomes, as reported previously (Cheng et al., 1998; Gregory et al., 2004). Among the UGT isoforms detected in the human liver microsomes, recombinant UGT1A1, UGT1A3, and UGT1A9 enzymes had considerably high T<sub>4</sub>-UGT activities. Furthermore, microsomal T<sub>4</sub>-glucuronidation activity in the human liver was closely correlated with the activity of  $\beta$ -estradiol 3-glucuronidation activity, which is mediated by either UGT1A1 or UGT1A9 (Senafi et al., 1994), while it showed no correlation with the glucuronidation activities toward trifluoroperazine, a typical substrate of UGT1A4 (Court 2005; Dehal et al., 2001) and propofol, a typical substrate of UGT1A9 (Burchell et al., 1995). In addition to the results, T<sub>4</sub>-glucuronidation activity in human liver microsomes was significantly inhibited by either bilirubin, an inhibitor of UGT1A1 (Senafi et al., 1994; King et al., 1996), or ST232, an inhibitor of UGT1A3 (Kasai et al., 2005), but not propofol, an inhibitor of UGT1A9 (Burchell et al., 1995), indicating strongly that UGT1A1 and UGT1A3 enzymes, but not UGT1A9, mainly mediated the T<sub>4</sub>-glucuronidation in human microsomes. All these findings indicate that T<sub>4</sub>-UGT activity in the human liver is mainly dependent on the levels of UGT1A1 and UGT1A3 and further suggest that the inter-individual difference among humans in T<sub>4</sub>-glucuronidation activity would come

from difference in the levels of the UGT isoforms.

Although UGT1A1 had been reported to be an important enzyme for hepatic T<sub>4</sub>-glucuronidation in humans (Visser et al., 1993; Findlay et al., 2000; Yamanaka et al., 2007), the present findings further confirm this. On the other hand, importance of UGT1A3 for hepatic T<sub>4</sub>-glucuronidation in humans was firstly demonstrated in the present experiments, while Yamanaka et al. (2007) had reported that UGT1A3 would little contribute to the T<sub>4</sub>-glucuronidation. Thus difference concerning significance of UGT1A3 for T<sub>4</sub>-glucuronidation would come from the difference in the experimental methods rather than that in human samples. Yamanaka et al. (2007) lead to the conclusion on the basis of the results that microsomal activity for chenodeoxycholic acid 24-*O*-glucuronidation, which is thought to be catalyzed by UGT1A3 (Trottier et al., 2006), was not correlated with the T<sub>4</sub>-glucuronidation activity and not inhibited by imipramine, an inhibitor of UGT1A3 and UGT1A4 (Nakajima et al., 2002). However, the results obtained only by the enzyme assays would not be enough for establishment of the conclusion that UGT1A3 would not contribute to T<sub>4</sub>-glucuronidation. In the present experiments, importance of UGT1A3 for T<sub>4</sub>-glucuronidation was more directly demonstrated not only by the inhibition assays with a selective inhibitor (ST232) of UGT1A3 but also by the correlation analysis between microsomal T<sub>4</sub>-glucuronidation activity and level of UGT1A3 in microsomes. In addition, the band detected by the Western blotting with anti-h1A3 antibody, which might show a cross-reactivity with UGT1A5, was judged as a UGT1A3 protein, because UGT1A3 mRNA, but not UGT1A5 mRNA, is detected in human liver (Tukey and Strassburg, 2000).

UGT1A8 and UGT1A10 are also reported as T<sub>4</sub>-glucuronidation enzymes (Visser et al., 1993; Findlay et al., 2000). However, these UGT isoforms would hardly

“DMD #18184”

contribute to hepatic T<sub>4</sub>-glucuronidation, because they are expressed in the intestine but little in the liver (Cheng et al., 1998; Gregory et al., 2004). In addition, UGT1A8 and UGT1A10 are considered to contribute to intestinal T<sub>4</sub>-glucuronidation (Yamanaka et al. (2007).

In conclusion, we demonstrate herein that UGT1A1 and UGT1A3 are important enzymes for hepatic T<sub>4</sub>-glucuronidation in humans and further suggest that the inter-individual difference in hepatic T<sub>4</sub>-glucuronidation activity would come from difference in the level of UGT1A1 and UGT1A3.

## References

- Barter RA and Klaassen CD (1992) Rat liver microsomal UDP-glucuronosyltransferase activity toward thyroxine: characterization, induction, and form specificity. *Toxicol Appl Pharmacol* **115**: 261-267.
- Burchell B, Brierley CH, and Rance D (1995) Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. *Life Sci* **57**: 1819–1831.
- Cheng Z, Radomska-Pandya A, and Tephly TR (1998) Cloning and expression of human UDP-glucuronosyltransferase (UGT) 1A8. *Arch Biochem Biophys* **356**: 301-305.
- Court MH (2005) Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. *Methods Enzymol* **400**: 104-116.
- Dehal SS, Gange PV, Crespi CL, and Patten CJ (2001) Characterization of a probe substrate and an inhibitor of UDP-glucuronosyltransferase 1A4 activity in human liver microsomes (HLM) and cDNA-expressed UGT-enzymes. *Drug Metab Rev* **33**(Suppl.1): 162.
- Findlay KAB, Kaptein E, Visser TJ, and Burchell B (2000) Characterization of the uridine diphosphate-glucuronosyltransferase-catalyzing thyroid hormone glucuronidation in man. *J Clin Endocr Metab* **85**: 2879-2883.
- Green MD, Oтуру EM, and Tephly TR (1994) Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. *Drug Metab Dispos* **22**: 799-805.
- Gregory PA, Lewinsky RH, Gardner-Stephen DA, and Mackenzie PI (2004) Regulation



“DMD #18184”

- of UDP glucuronosyltransferases in the gastrointestinal tract. *Toxicol Appl Pharmacol* **199**: 354-363.
- Guéraud F, and Paris A (1998) Glucuronidation: a dual control. *General Pharmacol: The Vascular System* **31**: 683-688.
- Ikushiro S, Emi Y, and Iyanagi T (1995) Identification and analysis of drug-responsive expression of UDP-glucuronosyltransferase family 1 (UGT1) isoform in rat hepatic microsomes using anti-peptide antibodies. *Arch Biochem Biophys* **324**: 267-272.
- Ikushiro S, Emi Y, Kato Y, Yamada S, and Sakaki T (2006) Monospecific antipeptide antibodies against human hepatic UDP-glucuronosyltransferase 1A subfamily (UGT1A) isoforms. *Drug Metab Pharmacokinet* **21**: 70-74.
- Iyanagi T (2007) Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification. *Int Rev Cytol* **260**: 35-112.
- Kasai N, Sakaki T, Shinkyō R, Ikushiro S, Iyanagi T, Ohta M, and Inouye K (2005) Metabolism of 26,26,26,27,27,27-F<sub>6</sub>-1 $\alpha$ ,23S,25-trihydroxyvitamin D<sub>3</sub> by human UDP-glucuronosyltransferase 1A3\*. *Drug Metab Dispos* **33**: 102-107.
- King CD, Green MD, Rios GR, Coffman BL, Owens IS, Bishop WP, and Tephly TR (1996) The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase1.1\*<sup>1</sup>. *Arch Biochem Biophys* **332**: 92-100.
- Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. *Pharmacogenet. Genomics* **10**: 677-685.
- Nakajima M, Tanaka E, Kobayashi T, Ohashi N, Kume T, and Yokoi T (2002)

“DMD #18184”

- Imipramine *N*-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms. *Drug Metab Dispos* **30**: 636-642.
- Radomska-Pandya A, Czernik PJ, Little JM, Battaglia E, and Mackenzie PI (1999) Structural and functional studies of UDP-glucuronosyltransferases. *Drug Metab Rev* **31**: 817-899.
- Senafi SB, Clarke DJ, and Burchell B (1994) Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. *Biochem J* **303**: 233-240.
- Trottier J, Verreault M, Grepper S, Monté D, Bélanger J, Kaeding J, Caron P, Inaba T, and Barbier O (2006) Human UDP-glucuronosyltransferase (UGT) 1A3 enzyme conjugates chenodeoxycholic acid in the liver. *Hepatology* **44**: 1158-1170.
- Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. *Annu Rev Pharmacol Toxicol* **40**: 581-616.
- Visser TJ (1996) Pathways of thyroid hormone metabolism. *Acta Med Austriaca Heft* **1/2**: 10-16.
- Visser TJ, Kaptein E, Gijzel AL, de Herder WW, Ebner T, and Burchell B (1993) Glucuronidation of thyroid hormone by human bilirubin and phenol UDP-glucuronosyltransferase isoenzymes. *FEBS Lett* **324**: 358-360.
- Wu SY, Green WL, Huang WS, Hays MT, and Chopra IJ (2005) Alternate pathways of thyroid hormone metabolism. *Thyroid* **15**: 943-958.
- Yamanaka H, Nakajima M, Katoh M, and Yokoi T (2007) Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes. *Drug Metab Dispos* in press

“DMD #18184”

(Published June 25, 2007; doi: 10.1124/dmd.107.016097).

“DMD #18184”

### Footnotes

This work was supported in part by the Grant-in-Aid for Scientific Research (C) (nos. 18510061, Y.K.) from Japan Society for the Promotion of Science, the Grant-in-Aid for Scientific Research (B) (no. 19310042, Y.K.) from Japan Society for the Promotion of Science, and by a Health and Labour Sciences Research Grants for Research on Risk of Chemical Substances from Ministry of Health, Labour and Welfare of Japan.

### Legends for figures

**FIG. 1.** Chemical structure of 26,26,26,27,27,27-hexafluoro-1 $\alpha$ ,23(S),25-trihydroxyvitamin D<sub>3</sub> (ST232).

**FIG. 2.** T<sub>4</sub>-glucuronidation by recombinant human UGT isoforms.

Glucuronidation activity of the microsomes containing a recombinant human UGT isoform was examined in the reaction mixture containing 90  $\mu$ M T<sub>4</sub> with [<sup>125</sup>I]T<sub>4</sub> (40-65  $\mu$ Ci/ $\mu$ mol), as described in "Materials and Methods". V/E<sub>0</sub> (min<sup>-1</sup>) value of a UGT isoform was calculated on the basis of the content of UGT in microsomes.

**FIG. 3.** Comparison of microsomal T<sub>4</sub>-glucuronidation activity in individual human livers.

Microsomal glucuronidation activity was examined in the reaction mixture containing 90  $\mu$ M T<sub>4</sub> with [<sup>125</sup>I]T<sub>4</sub> (40-65  $\mu$ Ci/ $\mu$ mol), as described in "Materials and Methods". Each column represents the mean  $\pm$  SE (vertical bars) of triplicate determinations

**FIG. 4.** Relationship between hepatic microsomal activities for T<sub>4</sub>-glucuronidation and other chemicals ( $\beta$ -estradiol, trifluoperazine, and propofol)-glucuronidation in humans.

Human samples: HG3, ①; HH13, ②; HG32, ③; HH47, ④; HG64, ⑤; HG74, ⑥; HH2, ⑦. Lines represent the best-fit estimate of least-squares linear regression analysis. A correlation coefficient of regression (*r*) is shown for each plot.

“DMD #18184”

**FIG. 5.** Immunoblot analysis of hepatic microsomal UGT isoforms in 7 individual humans.

The immunoblot analyses with human-UGT1A antibody and isoform-specific antibody (anti-h1A1, anti-h1A3, anti-h1A9, or anti-2B7) were performed using 20  $\mu$ g and 40  $\mu$ g protein/lane of hepatic microsomes, respectively.

**FIG. 6.** Correlation analysis between the T<sub>4</sub>-glucuronidation activity and the content of UGT1A isoforms in the human liver microsomes.

Semiquantitative immunoblot analyses for UGT1A, UGT1A1, UGT1A3, and UGT1A9 in the human liver microsomes were performed according to the method as described in the legend of Fig. 4. Human samples: HG3, ①; HH13, ②; HG32, ③; HH47, ④; HG64, ⑤; HG74, ⑥; HH2, ⑦. Line represents the best-fit estimate of least-squares linear regression analysis. A correlation coefficient of regression (*r*) is shown for each plot. Net intensity values were expressed relative to the content of respective UGT isoforms in HG3.

**FIG. 7.** Effects of several UGT inhibitors on microsomal T<sub>4</sub>-glucuronidation in the human liver.

Bilirubin, ST232, propofol, and  $\beta$ -estradiol were used as inhibitors for UGT1A1, UGT1A3, UGT1A9 and UGT1A1/UGT1A9, respectively. Basal activity (without an inhibitor) in the human liver (HH13) was  $17.6 \pm 0.3$  pmol/mg protein/min. ○, Bilirubin; □, ST232; ▲, propofol; ◆,  $\beta$ -estradiol. Each point represents the mean  $\pm$  SE (vertical bars) for 4 preparations.

“DMD #18184”

\* $P < 0.01$ , significantly different from the control.

“DMD #18184”


**Table 1.** Effect of alamethicin on microsomal T<sub>4</sub>-glucuronidation activity in the human liver

Alamethicin (mg/ml reaction mixture)	T <sub>4</sub> -glucuronidation (pmol/mg protein/min)
0	5.9 ± 0.2
0.04	15.0 ± 1.0
0.1	15.6 ± 0.4
0.2	17.0 ± 0.3

Data represent the mean ± SE for 4 preparations.



Fig. 1



ST232

Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7

